Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,770 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, erlotinib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
Interventions
NXP900, Osimertinib
Drug
Lead sponsor
Nuvectis Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Calverton, Maryland • Boston, Massachusetts • Eugene, Oregon + 3 more
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Conditions
C-Met Exon 14 Mutation
Interventions
Glumetinib
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Louisville, Kentucky
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Loma Linda, California • Whittier, California • Newark, Delaware + 13 more
Conditions
Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
Interventions
EDP1503, Pembrolizumab
Biological
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Conditions
Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 10 more
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Conditions
Non-small Cell Lung Cancer
Interventions
canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab
Radiation · Drug · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, erlotinib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Sacramento, California
Conditions
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
Interventions
PF-07265028, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
127
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Conditions
Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Interventions
ONC201
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine, Docetaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774)
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Conditions
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions
Mifepristone and Eribulin in combination
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more
Conditions
Non-small Cell Lung Cancer
Interventions
bexarotene
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Pasadena, California + 17 more
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Seattle, Washington